• 1
    World Health Organization. Cardiovascular Disease and Steroid Hormone Contraception. Report of a WHO Scientific group. WHO Technical Report Series 877. Geneva: World Health Organization, 1998.
  • 2
    Lemaitre RN, Heckbert SR, Psaty BM, Smith NL, Kaplan RC, Longstreth WT Jr. Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch Intern Med 2002; 162: 195460.
  • 3
    Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 9807.
  • 4
    Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain, 1996–2000. BJOG 2002; 109: 131930.
  • 5
    Jordan WM. Pulmonary embolism. Lancet 1961; ii: 11467.
  • 6
    Lorentz I. Parietal lesions and Enavid. BMJ 1962; ii: 1191.
  • 7
    Boyce J, Fawcett JW, Noall EWP. Coronary thrombosis and Conovid. Lancet 1963; i: 111.
  • 8
    The Coronary Drug Project Research Group. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 1973; 226: 6527.
  • 9
    Van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 33742.
  • 10
    Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 97780.
  • 11
    Jick H, Derby LE, Wald Myers M, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 9813.
  • 12
    Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 9837.
  • 13
    Rossouw JE, Anderson GL, Prentice RL, Lacroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 32133.
  • 14
    Virchow R. Phlogose und Thrombose im Gefäßsystem. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt: Staatsdruckerei, 1856.
  • 15
    Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297301.
  • 16
    Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 116773.
  • 17
    Henzl MR, Edwards JA. Pharmacology of progestins. 17-alpha-hydroxyprogesterone derivatives and progestins of the first and second generation. In: Sitruk-WareR, MishellDR, eds. Progestins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, 2000: 10132.
  • 18
    Van Vloten WA, Van Haselen CW, Van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69 (Suppl. 4): 215.
  • 19
    Kuhnz W, Staks T, Jutting G. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. Contraception 1993; 48: 55775.
  • 20
    Lachnit-Fixson U. The development and evaluation of an ovulation inhibitor (DIAne) containing an antiandrogen. Acta Obstet Gynecol Scand Suppl 1979; 88: 3342.
  • 21
    Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995; 761: 31135.
  • 22
    Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 181621.
  • 23
    Records Unit and Research Advisory Service of the Royal College of General Practitioners. Oral contraception and thromboembolic disease. J R Coll General Pract 1967; 13: 26779.
  • 24
    Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ 1968; i: 199205.
  • 25
    Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. BMJ 1969; ii: 6517.
  • 26
    Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am J Epidemiol 1969; 90: 36580.
  • 27
    Anonymous. Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall bladder disease and breast tumours. Lancet 1973; i: 1399404.
  • 28
    Porter JB. Oral contraceptives and nonfatal vascular disease – recent experience. Obstet Gynecol 1982; 59: 299302.
  • 29
    Royal College of General Practioners' Oral Contraception Study. Oral contraceptives, venous thrombosis, and varicose veins. J R Coll General Pract 1978; 28: 3939.
  • 30
    Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986; 292: 526.
  • 31
    Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med 1995; 238: 317.
  • 32
    Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 14537.
  • 33
    Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 4852.
  • 34
    World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 157582.
  • 35
    Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low-oestrogen oral contraceptives. J Obst Gynecol 1995; 15: 195200.
  • 36
    Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 11905.
  • 37
    Brandjes DP, Büller HR, Heijboer H, Huisman MV, De Rijk M, Jagt H, Ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 75962.
  • 38
    Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 4952.
  • 39
    Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 1278.
  • 40
    Saleh WA, Burkman RT, Zacur HA, Kimball AW, Kwiterovich P, Bell WK. A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels. Am J Obstet Gynecol 1993; 168: 17405.
  • 41
    Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 327.
  • 42
    Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 15936.
  • 43
    World Health Organization. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 15828.
  • 44
    Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 158993.
  • 45
    Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 1314.
  • 46
    Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 14279.
  • 47
    Sheldon T. Dutch GPs warned against new contraceptive pill. BMJ 2002; 324: 869.
  • 48
    Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 11829.
  • 49
    Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factors and oral contraceptive use. Thromb Haemost 2003; 89: 4938.
  • 50
    Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, Gavasso S, Huisman MV, Büller HR, Ten Cate JW, Girolami A, Prins MH. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198202.
  • 51
    Martinelli I, De Mannucci PMSV, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G, Faioni EM. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 23538.
  • 52
    Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 15048.
  • 53
    Rintelen C, Mannhalter C, Ireland H, Lane DA, Knobl P, Lechner K, Pabinger I. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93: 48790.
  • 54
    Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 7003.
  • 55
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698703.
  • 56
    Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 1525.
  • 57
    Van Hylckama Vlieg A, Van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 367882.
  • 58
    Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696701.
  • 59
    De Visser MCH, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X and the risk of venous thrombosis. Thromb Haemost 2001; 85: 10117.
  • 60
    Van Hylckma Vlieg A, Rosendaal FR. Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis. J Thromb Haemost 2003; 1: in press.
  • 61
    Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. BMJ 1975; 2: 2415.
  • 62
    Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol 1980; 111: 5966.
  • 63
    Shapiro S, Slone D, Rosenberg L, Kaufman DW, Stolley PD, Miettinen OS. Oral-contraceptive use in relation to myocardial infarction. Lancet 1979; i: 7437.
  • 64
    Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. JAMA 1978; 240: 254852.
  • 65
    Jick H, Porter J, Rothman KJ. Oral contraceptives and nonfatal stroke in healthy young women. Ann Intern Med 1978; 89: 5860.
  • 66
    Jick H, Dinan B, Rothman KJ. Oral contraceptives and nonfatal myocardial infarction. JAMA 1978; 239: 14036.
  • 67
    Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981; 305: 6128.
  • 68
    Stadel BV. Oral contraceptives and cardiovascular disease (second of two parts). N Engl J Med 1981; 305: 6727.
  • 69
    World Health Organization. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997; 349: 12029.
  • 70
    World Health Organization. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348: 498505.
  • 71
    Van Den Bosch MAAJ, Kemmeren JM, Tanis BC, Mali WPTM, Helmerhorst FM, Rosendaal FR, Algra A, Van Der Graaf Y. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost 2003; 1: 43944.
  • 72
    Kemmeren JM, Tanis BC, Van Den Bosch MA, Bollen EL, Van Der Helmerhorst FM, Van Der Graaf Y, Rosendaal FR, Algra A. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33: 12028.
  • 73
    Tanis BC, Van Den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, Van Der Graaf Y, Rosendaal FR. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 178793.
  • 74
    Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 137581.
  • 75
    Jick H, Jick S, Myers MW, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 1996; 347: 6278.
  • 76
    Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56: 12940.
  • 77
    Dunn N, Thorogood M, Faragher B, De Caestecker L, MacDonald TM, McCollum C, Thomas S, Mann R. Oral contraceptives and myocardial infarction: results of the MICA case-control study. Br Med J 1999; 318: 157984.
  • 78
    Sidney S, Siscovick DS, Petitti DB, Schwartz SM, Quesenberry CP, Psaty BM, Raghunathan TE, Kelaghan J, Koepsell TD. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998; 98: 105863.
  • 79
    Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 281721.
  • 80
    Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 174750.
  • 81
    Doggen CJM, Manger Cats V, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 103741.
  • 82
    The Atherosclerosis, Thrombosis and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 111722.
  • 83
    MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2001:CD002978.
  • 84
    Watts NB. Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results. J Reprod Med 2002; 47 (Suppl. 1): 8292.
  • 85
    Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA 2001; 286: 81520.
  • 86
    Doren M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update 2000; 6: 41926.
  • 87
    Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet 1979; 2: 7059.
  • 88
    Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 11958.
  • 89
    Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 5866.
  • 90
    Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313: 10449.
  • 91
    Psaty BM, Heckbert SR, Atkins D, Siscovick DS, Koepsell TD, Wahl PW, Longstreth WT Jr, Weiss NS, Wagner EH, Prentice R. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med 1993; 153: 14217.
  • 92
    Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, Tyroler HA, Rifkind BM. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA 1983; 249: 9036.
  • 93
    Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; i: 85860.
  • 94
    Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979; 53: 27781.
  • 95
    Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet Gynecol 1993; 82: 10218.
  • 96
    Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol 1993; 46: 2119.
  • 97
    Posthuma WF, Westendorp RG, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994; 308: 12689.
  • 98
    Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996; 348: 1027.
  • 99
    Varas Lorenzo C, Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998; 147: 38790.
  • 100
    Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796800.
  • 101
    Grady D, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 1997; 278: 477.
  • 102
    Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghoke D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med 2000; 132: 68996.
  • 103
    Høibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism – a population-based case-control study. Thromb Haemost 1999; 82: 121821.
  • 104
    Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45–64 years: relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 5305.
  • 105
    Herrington DM, Vittinghoff E, Howard TD, Major DA, Owen J, Reboussin DM, Bowden D, Bittner V, Simon JA, Grady D, Hulley SB. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22: 10127.
  • 106
    Høibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrøm E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy – results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 9617.
  • 107
    Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittingoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 60513.
  • 108
    Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 4957.
  • 109
    The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo-controlled trial. Lancet 2002; 360: 20018.
  • 110
    Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, Lacroix AZ, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident non-fatal myocardial infarction. JAMA 2001; 285: 90613.
  • 111
    Lemaitre RN, Psaty BM, Heckbert SR, Smith NL, Longstreth WT Jr, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal ischemic stroke in postmenopausal women. Arterioscler Thromb Vasc Biol 2002; 22: 10512.
  • 112
    Reiner AP, Heckbert SH, Vos HL, Ariens RA, Lemaitre RN, Smith NL, Lumley T, Rea TD, Hindorff LA, Schellenbaum GD, Rosendaal FR, Siscovick DS, Psaty BM. Genetic variants of coagulation factor XIII, post-menopausal estrogen therapy, and risk of non-fatal myocardial infarction. Blood 2002; 27 Nov (epub ahead of print).
  • 113
    Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize L, Samama MM. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity. Thromb Haemost 1995; 74: 92832.
  • 114
    Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 1996; 76: 72934.
  • 115
    World Heath Organization. Task force on oral contraceptives: A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br J Obstet Gynaecol 1991; 98: 111728.
  • 116
    Meade TW, Haines AP, North WR, Chakrabarti R, Howarth DJ, Stirling Y. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet 1977; ii: 94851.
  • 117
    Olivieri O, Friso S, Manzato F, Guella A, Bernardi F, Lunghi B, Girelli D, Azzini M, Brocco G, Russo C et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 46570.
  • 118
    Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, Peverill RE. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20: 14049.
  • 119
    Koh KK, Horne MK III, Cannon RO III Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost 1999; 82: 62633.
  • 120
    Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 71722.
  • 121
    Åstrup T. The haemostatic balance. Thromb Diath Haemorrh (Stutt) 1958; 2: 34757.
  • 122
    Henkens CM, Bom VJ, Seinen AJ, Van Der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 4024.
  • 123
    Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 203640.
  • 124
    Middeldorp S, Meijers JCM, Van Den Ende AE, Van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Buller HR. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 48.
  • 125
    Tans G, Curvers J, Middeldorp S, Thomassen MCLGD, Meijers JCM, Prins MH, Bouma BN, Buller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 1521.
  • 126
    Meijers JCM, Middeldorp S, Tekelenburg W, Van Den Ende AE, Tans G, Prins MH, Rosing J, Buller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000; 84: 914.
  • 127
    Rosing J, Tans G, Nicolaes GA, Thomassen MC, Van Oerle R, Van der Ploeg PM, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 2338.
  • 128
    Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost 2002; 87: 199205.
  • 129
    Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, Schenck-Gustafsson K, Smith SC Jr, Taubert KA, Wenger NK; American Heart Association. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499503.
  • 130
    Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, Lowe GD. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 8514.
  • 131
    Walker AM, Martin-Moreno JM, Artalejo FR. Odd man out: a graphical approach to meta-analysis. Am J Public Health 1988; 78: 9616.